论文部分内容阅读
[目的]用131I标记抗人肿瘤分泌IgG轻链单克隆抗体(ATILCMcAb)进行荷瘤裸鼠体内生物分布与显像研究,探讨其在放射免疫显像及靶向治疗中的应用前景。[方法]采用氯胺-T法标记,SephadexG-25柱层析分离纯化,纸层析法测定标记率和放化纯度。BALB/c裸鼠右侧腹股沟皮下注射宫颈癌上皮细胞(HeLa MR),待肿瘤长至1cm左右,进行荷瘤裸鼠体内生物分布与显像实验。对照组为mIgG蛋白。[结果]131I-ATILCMcAb标记率89.9%±4.72%(n=4),放射性比活度1.26MBq/μg,放化纯度98.1%±1.24%(n=4),于4℃冰箱及37℃正常人混合血清存放72h后,放化纯度仍>90%。131I-ATILCMcAb在血中的清除率较131I-mIgG快(P<0.001);除肝、膀胱和股骨外,各组织72h T/NT比值与131I-mIgG比较有显著性差异(P<0.05)。荷瘤裸鼠体内显像实验显示24~72h,ATILCMcAb使肿瘤部位清晰显像。[结论]ATILCMcAb能够通过与肿瘤分泌的IgG特异结合而实现对肿瘤的探测,具有较好的生物学特性,为进一步的放射免疫显像及靶向治疗研究奠定了实验基础。
[Objective] To study the biodistribution and imaging of tumor-bearing nude mice with 131I-labeled anti-human tumor-secreting IgG light chain monoclonal antibody (ATILCMcAb), and to explore its potential application in radioimmunoimaging and targeted therapy. [Method] The chloramine-T method was used for separation and purification by SephadexG-25 column chromatography. The labeling rate and radiochemical purity were determined by paper chromatography. Cervical carcinoma epithelial cells (HeLa MR) were subcutaneously injected into the right groin of BALB / c nude mice. When the tumors grew to about 1 cm in length, the biodistribution and imaging experiments were performed in nude mice. The control group was mIgG protein. [Result] The 131I-ATILC McAb labeling rate was 89.9% ± 4.72% (n = 4), the specific activity was 1.26MBq / μg and the radiochemical purity was 98.1% ± 1.24% (n = 4) Human mixed serum storage 72h, radiochemical purity is still> 90%. 131I-ATILCMcAb in the blood clearance rate than 131I-mIgG faster (P <0.001); except for the liver, bladder and femur, each tissue 72h T / NT ratio and 131I-mIgG significant difference (P <0.05). Tumor bearing nude mice in vivo imaging experiments showed 24 ~ 72h, ATILCMcAb clear imaging of the tumor site. [Conclusion] ATILCMcAb can detect the tumor by specifically binding to IgG secreted by the tumor and has good biological characteristics, which lays the foundation for further research on radioimmunoimaging and targeted therapy.